Subscribe
Follow Us
Subscribe
Follow Us

Silvanex™ HOSPITAL WOUND DRESSINGS

Silvanex™ hospital wound dressings provide unprecedented antimicrobial protection to support healthy wound healing in healthcare settings

The Need:

  • Silver is a mainstay antimicrobial ingredient used for over 45 years in medical wound dressings. Despite its mainstream use, many infectious microbes cannot be killed by the silver present in medical products due to antimicrobial resistance (AMR) [1-11]
  • Antimicrobial wound dressings are routinely used in healthcare settings for surgical wounds, IV line insertion sites, and chronic non-healing wounds to protect against infection
  • Despite modern infection control measures, wound infections remain the top form of Healthcare-Associated Infection (HAI) [12-15]
  • Treatment-resistant “superbug” infections kill 4.7 million people each year, and HAIs cost the U.S. $45 billion annually [12-17]

Understanding Hospital Wound Care

All types of wounds in healthcare settings must be properly cared for in order to prevent infection and support the body’s natural healing process. This requires that wounds are kept free of colonization by infection-causing microbes, and left minimally disturbed with sufficient moisture. In healthcare settings, this commonly involves the use of a primary wound dressing to contact the wound, absorb wound exudate, and help maintain a moist environment free of microbial colonization. Secondary dressings are commonly used to help secure the primary dressing to the wound site, and may involve a skin adhesive. Secondary dressings also help to regulate the flow of air and moisture to maintain the desired level of moisture. Some wound dressings are a 2-in-1 primary and secondary dressing together as a single product.

Silvanex™ hospital wound dressings contain a synergistic combination of silver, cannabichromene (CBC) and cannabigerol (CBG) to effectively prevent microbial colonization. Through a unique cell wall targeting mechanism of action, Silvanex™ overcomes antimicrobial resistance (AMR) to conventional silver offering unprecedented protection against all major classes of healthcare-associated pathogens, including anti-biofilm protection

Silvanex™ antimicrobial technology acts within the wound dressing to prevent microbial colonization in order to support the wound healing process

  • Overcomes antimicrobial resistance (AMR) with 800% improved effectiveness and faster onset of action compared to conventional silver technologies
  • Eradicates all major classes of healthcare-associated pathogens with a novel synergistic bactericidal & fungicidal mechanism
  • Lower silver content compared to conventional silver dressings limits the possibility of adverse effects
  • Proven effective against multi-drug resistant (MDR) “superbug” pathogens and treatment-resistant biofilms
  • Stops new antimicrobial resistance (AMR) from emerging

Silvanex™ hospital wound dressings are uniquely positioned to address

  • Surgical wounds
  • Chronic wounds, including venous leg ulcers and pressure ulcers
  • Moderate to heavily exuding wounds, including infected wounds
  • IV line insertion sites
Product Pipeline

Silvanex™ performance in hospital wound care

111 1
112 1
113 1
114 1
115 1
116 1
Silvanex™ hospital wound dressings are currently in pre-clinical development. To receive news and announcements on the advancement of Silvanex™ products subscribe to our mailing list.
  1. Vasishta R, Chhibber S, Saxena M. Heavy metal resistance in clinical isolates of Pseudomonas aeruginosa. Folia Microbiologica. 1989;34:448-52.
  2. McHugh GL, Moellering RC, Hopkins CC, Swartz MN. Salmonella typhimurium resistant to silver nitrate, chloramphenicol, and ampicillin. Lancet. 1975;1(7901):235-40.
  3. Terzioğlu E, Arslan M, Balaban BG, Çakar ZP. Microbial silver resistance mechanisms: recent developments. World J Microbiol Biotechnol. 2022;38(9):158.
  4. Randall CP, Gupta A, Jackson N, Busse D, O’Neill AJ. Silver resistance in Gram-negative bacteria: a dissection of endogenous and exogenous mechanisms. J Antimicrob Chemother. 2015;70(4):1037-46.
  5. Finley Phillip J, Norton R, Austin C, Mitchell A, Zank S, Durham P. Unprecedented Silver Resistance in Clinically Isolated Enterobacteriaceae: Major Implications for Burn and Wound Management. Antimicrobial Agents and Chemotherapy. 2015;59(8):4734-41.
  6. Hanczvikkel A, Füzi M, Ungvári E, Tóth Á. Transmissible silver resistance readily evolves in high-risk clone isolates of Klebsiella pneumoniae. Acta Microbiol Immunol Hung. 2018;65(3):387-403.
  7. Lok C-N, Ho C-M, Chen R, Tam PK-H, Chiu J-F, Che C-M. Proteomic Identification of the Cus System as a Major Determinant of Constitutive Escherichia coli Silver Resistance of Chromosomal Origin. Journal of Proteome Research. 2008;7(6):2351-6.
  8. Blanco Massani M, Klumpp J, Widmer M, Speck C, Nisple M, Lehmann R, et al. Chromosomal Sil system contributes to silver resistance in E. coli ATCC 8739. Biometals. 2018;31(6):1101-14.
  9. Sütterlin S, Edquist P, Sandegren L, Adler M, Tängdén T, Drobni M, et al. Silver resistance genes are overrepresented among Escherichia coli Isolates with CTX-M production. Appl Environ Microbiol. 2014;80(22):6863-9.
  10. Gupta A, Matsui K, Lo J-F, Silver S. Molecular basis for resistance to silver cations in Salmonella. Nature Medicine. 1999;5(2):183-8.
  11. Andira Pharmaceuticals data on file.
  12. Magill SS, Edwards JR, Bamberg W, et al. Emerging Infections Program Healthcare-Associated Infections and Antimicrobial Use Prevalence Survey Team. Multistate point-prevalence survey of health care-associated infections. N Engl J Med. 2014 Mar 27;370(13):1198-208. doi: 10.1056/NEJMoa1306801.
  13. Haque M, Sartelli M, McKimm J, et al. Health care-associated infections – an overview. Infect Drug Resist. 2018 Nov 15;11:2321-2333. doi: 10.2147/IDR.S177247. PMID: 30532565; PMCID: PMC6245375.
  14. Magill SS, Hellinger W, Cohen J, et al. Prevalence of healthcare-associated infections in acute care hospitals in Jacksonville, Florida. Infect Control Hosp Epidemiol. 2012 Mar;33(3):283-91. doi: 10.1086/664048. Epub 2012 Jan 12. PMID: 22314066; PMCID: PMC4648350.
  15. Cleveland Clinic Health Library (2024). Nosocomial Infections (Healthcare-Associated Infections). Available online: https://my.clevelandclinic.org/health/diseases/16397-avoiding-healthcare-associated-infections-hais
  16. Naghavi M, et. al., Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050. The Lancet. 2024 Sep;404(10459):1199-1226.
  17. Stone PW. Economic burden of healthcare-associated infections: an American perspective. Expert Review of Pharmacoeconomics & Outcomes Research. 2009;9(5):417–22. doi: 10.1586/erp.09.53 PMC2827870.

LATEST NEWS FROM ANDIRA

Join us in transforming the future of healthcare with our groundbreaking cannabinoid therapeutics and medical devices.

CONTACT US